LSD-Assisted Psychotherapy in Patients with Terminal Cancer
The DOI matches its Crossref record.
Abstract
The paper describes the results of a clinical study exploring the potential of a complex psychotherapeutic program utilizing psychedelic compounds to alleviate the emotional and physical suffering of cancer patients. A total of 60 cancer patients participated in this experimental study. In 44 of these patients, LSD (200-500 p%per os) was administered as an adjunct to psychotherapy; in 19 patients, a new psychedelic compound, dipropyltryptamine (DPT) was administered (60-105 mg i.m.). Three of these patients received both LSD and DPT administered on different sessions. The therapeutic results were assessed by means of a rating scale reflecting the degree of the patients’ depression, psychological isolation, anxiety, difficulty in management, fear of death, and pain. The ratings were done by attending physicians, nurses, family members, LSD therapists and cotherapists, and independent raters. In addition, the amount of narcotics required in the management of the patient was measured before and after the psychedelic sessions. Systematic rating was carried out in a group of 31 cancer patients treated by LSD. The comparison of the means of individual ratings from pre- to posttreatment showed significant improvement in all the measured parameters for most of the raters. There was a definite reduction of the narcotic medication; it did not, however, reach the level of statistical significance. The pre- to post-treatment comparison of the global indexes used as gross indicators of the degree of emotional and physical distress, indicated that approximately 29 % of the patients showed dramatic improvement, and another 41.9 % moderate improvement, with 22.6 % essentially unchanged. In 6.4 % of the patients, global indexes showed a decrement in the posttherapy ratings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Post-treatment, patients showed 'dramatic improvement' (29%) and 'moderate improvement' (42%), or remained 'essentially unchanged' (29%).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
In the citing paper
“No serious adverse effects were reported.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
In the citing paper
“Overall, improvements were reported on anxiety, depression, and social isolation.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
In the citing paper
“Additionally, while we found some qualitative studies detailing patient experiences with classical psychedelics (Grof et al., 1973;Agin-Liebes et al., 2020;Belser et al., 2017), no qualitative studies on ketamine treatment in terminally ill patients were encountered in the literature.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
Citations
Cites
Still being checked.
Cited by
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
“Several unblinded studies in the 1960s and 70s suggested that such compounds might be effective in treating psychological distress in cancer patients (Grof et al., 1973; Kast, 1967; Richards et al., 1977); however, these studies did not include the comparison conditions that would be expected of modern psychopharmacol…”
BackgroundSelf-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Gasser, P., Kirchner, K., & Passie, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114555249 · Cited by 456
Psychedelics, meditation, and self-consciousness
Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01475 · Cited by 390
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 411
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897615 · Cited by 360
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Holze, F., Gasser, P., Müller, F., Dolder, P. C., & Liechti, M. E. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.08.025 · Cited by 318
Majić, T., Schmidt, T. T., & Gallinat, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568040 · Cited by 261
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA
Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00576-3 · Cited by 239
dos Santos, R. G., Bouso, J. C., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1511424 · Cited by 227
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“…with dipropyltryptamine (DPT), a closely related synthetic analog of DMT, revealed some promise as an adjunct to psychotherapy both with alcoholics (Grof et al., 1973; Rhead et al., 1977; Soskin et al., 1973), and those with anxiety associated with a terminal cancer diagnosis (Richards et al.,…”
BackgroundInfluentialCan Drugs Be Used to Enhance the Psychotherapeutic Process?
Grinspoon, L., & Bakalar, J. B. (1986) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1986.40.3.393 · Cited by 187
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177
Attitude Change Following Near-Death Experiences
Noyes, R. (1980) · Psychiatry · doi:10.1080/00332747.1980.11024070 · Cited by 171
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171
“Early accounts (Grof et al., 1973; Grof and Halifax, 1978) propose the use of family photographs to facilitate the resolution of relational problems and to promote the emergence of positive feelings.”
BackgroundInfluentialSchimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06027-y · Cited by 162
Sarris, J. J., McIntyre, E., & Camfield, D. (2013) · CNS Drugs · doi:10.1007/s40263-013-0059-9 · Cited by 173
Yao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 174
Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R. J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., Bossis, A., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00020 · Cited by 139
The History of Psychedelics in Psychiatry
Nichols, D. E., & Walter, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1310-3990 · Cited by 133
Individual experiences in four cancer patients following psilocybin-assisted psychotherapy
Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac, S. K., Owens, L. T., Bossis, A. P., Belser, A. B., Agin-Liebes, G., Bogenschutz, M. P., & Ross, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00256 · Cited by 131
“These trials included several hundred participants and showed improvements in depression, anxiety, fear of dying, quality of life, and pain (Kast and Collins, 1964; Kast, 1966; Pahnke, 1969; Grof et al., 1973b).”
BackgroundMethodBogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., Ross, S., & Mennenga, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00100 · Cited by 128
Reiche, S., Hermle, L., Gutwinski, S., Jungaberle, H., Gasser, P., & Majić, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.012 · Cited by 122
“…transferred to the treatment of anxiety and depression in patients with a life-threatening disease (Kurland, 1985; Pahnke et al., 1970b), resulting in a total of three open-label pilot studies with terminal cancer patients (N = 112) (Grof et al., 1973; Pahnke et al., 1969; Richards et al., 1980).”
BackgroundMethodInfluentialSpirituality and nursing: a reductionist approach
Paley, J. (2007) · Nursing Philosophy · doi:10.1111/j.1466-769x.2007.00330.x · Cited by 149
Wasteson, E., Brenne, E., Higginson, I. J., Hotopf, M., Lloyd-Williams, M., Kaasa, S., Loge, J. H., & (EPCRC), T. E. P. C. R. C. (2009) · Palliative Medicine · doi:10.1177/0269216309106978 · Cited by 106
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Lewis, C. R., Preller, K. H., Kraehenmann, R., Michels, L., Staempfli, P., & Vollenweider, F. X. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.020 · Cited by 102
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress
Ross, S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1482261 · Cited by 102
Jansen, K. L. R. (1990) · Medical Hypotheses · doi:10.1016/0306-9877(90)90048-j · Cited by 115
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
“given the increased suggestibility and acutely heightened environmental sensitivity [130,143,183].”
BackgroundInfluentialGregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 103
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
Ramaekers, J. G., Hutten, N., Mason, N. L., Dolder, P., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., & Kuypers, K. P. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120940937 · Cited by 92
Hallucinogenic Drugs in Psychiatric Research and Treatment Perspectives and Prospects
STRASSMAN, R. J. (1995) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199503000-00002 · Cited by 90
Psychedelics and music: neuroscience and therapeutic implications
Barrett, F. S., Preller, K. H., & Kaelen, M. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1484342 · Cited by 86
Therapeutic Applications of Classic Hallucinogens
Bogenschutz, M. P., & Ross, S. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_464 · Cited by 109
Novel antidepressant drugs: Beyond monoamine targets
Gonda, X., Döme, P., Neill, J. C., & Tarazi, F. I. (2021) · CNS Spectrums · doi:10.1017/s1092852921000791 · Cited by 91
Lower-dose psycholytic therapy – A neglected approach
Passie, T., Guss, J., & Krähenmann, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1020505 · Cited by 81
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959604 · Cited by 85
Moreton, S. G., Szalla, L., Menzies, R. E., & Arena, A. F. A. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05391-0 · Cited by 93
Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in Pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 72
Structural neural plasticity evoked by rapid-acting antidepressant interventions
Liao, C., Dua, A. N., Wojtasiewicz, C., Liston, C. M., & Kwan, A. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00876-0 · Cited by 87
Raut, S. B., Marathe, P. A., van Eijk, L., Eri, R. D., Ravindran, M., Benedek, D. M., Ursano, R. J., Canales, J. J., & Johnson, L. R. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108195 · Cited by 84
Ross, S., Agrawal, M., Griffiths, R. R., Grob, C. S., Berger, A. M., & Henningfield, J. E. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109174 · Cited by 81
Drug–drug interactions involving classic psychedelics: A systematic review
Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 80
The Use of Hallucinogens in the Treatment of Addiction
Halpern, J. H. (1996) · Addiction Research · doi:10.3109/16066359609010756 · Cited by 63
Maia, L. O., Beaussant, Y., & Garcia, A. C. M. (2022) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2022.01.024 · Cited by 60
Kolp, E., Friedman, H. L., University of Florida, Krupitsky, E., St. Petersburg State Pavlov Medical University, Jansen, K., Hospital, A., Sylvester, M., Young, M. S., University of South Florida, et al. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.84 · Cited by 54
Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
Ross, S. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.04.002 · Cited by 57
Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics
Glowacki, D. R., Wonnacott, M. D., Freire, R., Glowacki, B. R., Gale, E. M., Pike, J. E., de Haan, T., Chatziapostolou, M., & Metatla, O. (2020) · Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems · doi:10.1145/3313831.3376649 · Cited by 54
Gallimore, A. R., & Strassman, R. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00211 · Cited by 52
Grob, C. S., Bossis, A. P., & Griffiths, R. R. (2013) · Psychological Aspects of Cancer · doi:10.1007/978-1-4614-4866-2_17 · Cited by 53
Whelan, A., & Johnson, M. I. (2018) · Pain Management · doi:10.2217/pmt-2017-0068 · Cited by 51
Magaraggia, I., Kuiperes, Z., & Schreiber, R. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107467 · Cited by 49
Rosa, W. E., Sager, Z. S., Miller, M. E., Bernstein, I., Rinaldi, A. D., Addicott, K., Ljuslin, M., Adrian, C., Back, A. L., Beachy, J., et al. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0036 · Cited by 54
Self-citationArgyri, E. K., Evans, J., Luke, D. P., Michael, P., Michelle, K., Rohani-Shukla, C., Suseelan, S., Prideaux, E., McAlpine, R. G., Murphy-Beiner, A., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322501 · Cited by 59
Kolp, E., Young, M. S., Florida Mental Health Institute of University of South Florida, Friedman, H., University of Florida, Krupitsky, E., St. Petersburg State Pavlov Medical University, Jansen, K., O’Connor, L.-A., & Argosy University (2007) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2007.26.1.1 · Cited by 45
Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 44
Bornemann, J., Close, J. B., Spriggs, M. J., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.735427 · Cited by 53
Schipper, S., Nigam, K. B., Schmid, Y., Piechotta, V., Ljuslin, M., Beaussant, Y., Schwarzer, G., & Boehlke, C. S. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015383.pub2 · Cited by 65
Halpern, J. H. (2003) · Current Psychiatry Reports · doi:10.1007/s11920-003-0067-4 · Cited by 44
Beaussant, Y., Sanders, J. J., Sager, Z. S., Tulsky, J. A., Braun, I. M., Blinderman, C. D., Bossis, A. P., & Byock, I. R. (2020) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0603 · Cited by 48
Ethnopharmacology and Taxonomy of Mexican Psychodysleptic Plants
Díaz, J. L. (1979) · Journal of Psychedelic Drugs · doi:10.1080/02791072.1979.10472094 · Cited by 42
Are psychedelics the answer to chronic pain: A review of current literature
Kooijman, N. I., Willegers, T., Reuser, A. M., Mulleners, W. M., Kramers, C., Vissers, K. C. P., & van der Wal, S. E. I. (2023) · Pain Practice · doi:10.1111/papr.13203 · Cited by 52
Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy
Thal, S. B., Bright, S. J., Sharbanee, J. M., Wenge, T., & Skeffington, P. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.617224 · Cited by 41
Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness
Beaussant, Y., Tulsky, J. A., Guérin, B., Schwarz-Plaschg, C. G., Sanders, J. J., Beaussant, Y., Sanders, J. J., Guérin, B., Schwarz-Plaschg, C. G., Agrawal, M., et al. (2021) · Journal of Palliative Medicine · doi:10.1089/jpm.2020.0764 · Cited by 41
Self-citationShamanism and Altered States of Consciousness: An Introduction
de Rios, M. D., & Winkelman, M. (1989) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1989.10472137 · Cited by 36
Yang, K. H., Han, B. H., & Palamar, J. J. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107343 · Cited by 38
Psilocybin and Other Classic Psychedelics in Depression
Nutt, D. J., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_451 · Cited by 43
The Potential of Psychedelics for End of Life and Palliative Care
Yaden, D. B., Nayak, S. M., Gukasyan, N., Anderson, B. T., & Griffiths, R. R. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_278 · Cited by 39
Use of Psychedelics for Pain: A Scoping Review
Goel, A., Rai, Y., Sivadas, S., Diep, C., Clarke, H. A., Shanthanna, H., & Ladha, K. S. (2023) · Anesthesiology · doi:10.1097/aln.0000000000004673 · Cited by 38
Reynolds, L., Akroyd, A., Sundram, F., Stack, A., Muthukumaraswamy, S. D., & Evans, W. J. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18158160 · Cited by 39
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
Kaplar, M. E., Wachholtz, A., & O’Brien, W. H. (2004) · Journal of Psychosocial Oncology · doi:10.1300/j077v22n01_03 · Cited by 32
The Role of Psychedelics and Counseling in Mental Health Treatment
Curtis, R., Roberts, L. C., Graves, E. G., Rainey, H. T., Wynn, D. D., Krantz, D., & Wieloch, V. (2020) · Journal of Mental Health Counseling · doi:10.17744/mehc.42.4.03 · Cited by 37
Tiwari, P., Davoudian, P. A., Kapri, D., Vuruputuri, R. M., Karaba, L. A., Sharma, M., Zanni, G., Balakrishnan, A., Chaudhari, P. R., Pradhan, A., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.08.016 · Cited by 35
Psychedelics as preventive treatment in headache and chronic pain disorders
Schindler, E. A. D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109166 · Cited by 31
Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study
Cavarra, M., Mason, N., Kuypers, K., Bonnelle, V., Smith, W. J., Feilding, A., Kryskow, P., & Ramaekers, J. (2023) · European Journal of Pain · doi:10.1002/ejp.2171 · Cited by 26
Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models
Kyzar, E. J., & Kalueff, A. V. (2016) · Zebrafish · doi:10.1089/zeb.2016.1251 · Cited by 32
Cancer, emotions and mental illness: the present state of understanding
Surawicz, F. G., Brightwell, D. R., Weitzel, W. D., & Othmer, E. (1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.11.1306 · Cited by 28
Cox, D. J., Garcia‐Romeu, A., & Johnson, M. W. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2021.1910830 · Cited by 25
The Heffter Research Institute: Past and Hopeful Future
Nichols, D. E. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.873688 · Cited by 27
Predictors and potentiators of psychedelic-occasioned mystical experiences
Gandy, S. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00198 · Cited by 33
Can Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect?
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2019) · Journal of Cognitive Enhancement · doi:10.1007/s41465-019-00151-6 · Cited by 27
DPT as an Adjunct in Brief Psychotherapy with Cancer Patients
Richards, W. A., Rhead, J. C., Grof, S., Goodman, L. E., Di Leo, F., & Rush, L. (1980) · OMEGA - Journal of Death and Dying · doi:10.2190/ngub-v4rm-t7dc-xth3 · Cited by 20
Self-citationMacrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Kaypak, A. C., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119386 · Cited by 24
Psychedelics in the Treatment of Headache and Chronic Pain Disorders
Schindler, E. A. D. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_365 · Cited by 20
Psychedelics for Patients With Cancer: A Comprehensive Literature Review
White, C. M., Weisman, N., & Dalo, J. D. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221144055 · Cited by 19
Wolfson, P. E. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.160 · Cited by 20
Inserra, A., Piot, A., Gregorio, D. D., & Gobbi, G. (2023) · CNS Drugs · doi:10.1007/s40263-023-01008-5 · Cited by 24
Psychedelics and disorders of consciousness: the current landscape and the path forward
Cardone, P., Alnagger, N., Annen, J., Bicego, A., Gosseries, O., & Martial, C. (2024) · Neuroscience of Consciousness · doi:10.1093/nc/niae025 · Cited by 19
Metadata
- Authors
- Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A.
- ORCID
- Richards, W.A.
- Venue
- International Pharmacopsychiatry
- Publisher
- S. Karger AG
- Published
- 2017-08-11
- Volume
- 8
- Issue
- 3
- Pages
- 129-144
- ISSN
- 0020-8272 (ISSN-L)
- 2504-2580
- OpenAlex
- W173089895
- Cited by
- 209
- References
- 0
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 19 · 2021: 15 · 2020: 13 · 2019: 9 · 2018: 10 · 2017: 4
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- International Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- lysergic acid diethylamide, psychedelic therapy, terminal cancer, end-of-life care, depression, anxiety, psychological isolation, fear of death, pain management, emotional distress
- MeSH terms
- Adult, Aged, Anxiety, Attitude to Death, Clinical Trials as Topic, Depression, Female, Humans, Lysergic Acid Diethylamide, Male, Middle Aged, MMPI, Narcotics, Neoplasms, Palliative Care, Psychiatric Status Rating Scales, Psychotherapy, Terminal Care, Tryptamines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.